Personalized Treatment Approaches of Myopathies Based on Antibodies: Suur Bilicier, MD

Video

The associate professor of neurology at the University of Texas Health Science Center at Houston talked about advances in the classification of inflammatory myopathies at the recently concluded 2023 MDA conference. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

“The new classification of inflammatory myopathies [is an important to highlight]. Polymyositis is now becoming rarer; it wasn't as frequent as we thought it was. It's being pushed out or down to the classification, that's one important thing. The second thing is the new knowledge on antibodies in immune mediated myopathies or idiopathic inflammatory myopathies. Each antibody provides more insight for us as to what we need to do for our patients. In another word, it provides a custom customized approach, diagnostic approach and treatment approach for our patients.”

Neuromuscular medicine is an ever-evolving field that has seen significant advancements in recent years, propelled by dedicated research efforts. Myositis, a group of inflammatory muscle diseases, and the lingering unmet needs of these patients, remains a major topic of conversation among clinicians.

Recently, Suur Bilicier, MD, associate professor of neurology at the University of Texas Health Science Center at Houston, presented a talk on therapeutic approaches in myositis based on antibodies at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas. The session comprised of 5 talks given by experts in neuromuscular medicine and centered around topics of myositis including inclusion body myositis, idiopathic inflammatory myopathies and cancer, dermamyositis, polymyositis, and immune mediated necrotizing myopathy.

Bilicier, a neuromuscular specialist at UTHealth Houston, McGovern Medical School, sat down with NeurologyLive® in an interview at the conference to provide an overview of the topics discussed in the session. In addition, she discussed the important highlights of the session that neurologists who care for patients with myositis should be informed about. She also talked about the role of antibodies in myositis and tumorigenesis which are currently being explored by researchers.

Click here for more coverage of MDA 2023.

REFERENCES
1. Bilicier, S. Dermatomyositis: A Diagnostic and Therapeutic Approach Based on Antibodies. Presented at: MDA Clinical & Scientific Conference; March 19-22, 2023; Dallas, TX. Lab to Life: Myositis session.
Related Videos
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.